Company Active LTD

Company profile

Ostara Biomedical Limited

ERROR: The requested URL could not be retrieved

Ostara Biomedical Limited is a UK company with status active founded in 2012.

CRN
08322823
Founded
2012
Age
13

Overview

Legal name
OSTARA BIOMEDICAL LIMITED
Region
Unknown
Registered address
Unknown
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

1 event
07 Dec
2012

Incorporated

Inception

Company registered at Companies House

Public funding

5 awards
First funded
2014
Funded years
2014, 2017, 2020, 2021
Age at first award
1 years

Projects

2021 Feasibility Studies

SemenRate Canada/UK: Transforming Germplasm and Genetic Quality to Drive Livestock Productivity

1 Mar 2021 to 31 Jul 2023

Awarded
£84,244
Total cost £120,349

Good fertility performance is the cornerstone of a profitable and sustainable livestock enterprise. In the international dairy and beef herd, optimum performance is achieved by maintaining a calving interval (CI) of 365 days. Every day CI increases \>365 days is estimated to directly cost the farmer ~GBP2.07/CAN$3.54/cow, or more for high yielding dairy c...

2020 Study Lead participant

Superovulation without hormones - developing a novel, non-invasive method to induce follicular growth

1 Jan 2020 to 31 Mar 2022

Awarded
£404,722
Total cost £578,174

The creation of genetically modified (transgenic) animal models, primarily mice and rats, has revolutionised our understanding of human disease. Transgenic biotechnologies utilise large numbers of animals: both females and males to generate embryos for genetic manipulation, females to provide a host uterus to support the development of transgenic embryos,...

2017 Collaborative R&D Lead participant

ProgenySys - Reducing numbers in laboratory animal models through improved artificial reproduction rates

1 Aug 2017 to 30 Apr 2019

Awarded
£324,671
Total cost £721,490

The creation of genetically modified animals, primarily mice and rats, has revolutionised our understanding of disease processes in animal models. Transgenic biotechnologies utilise large numbers of animals: females and males to generate embryos for genetic manipulation, females to provide a host uterus to support the development of embryos, and infertile...

2017 Feasibility Studies Lead participant

REDLAB Going Global - REDucing LABoratory Rodent Numbers by driving adoption of UK Technology

1 Jan 2017 to 31 Mar 2017

Awarded
£19,222
Total cost £27,460

The creation of genetically modified animals, primarily mice and rats, has revolutionised understanding of disease processes in animal models. Transgenic biotechnologies utilise large numbers of animals: females and males to generate embryos for genetic manipulation, females to provide a host uterus to support the development of embryos, and infertile mal...

2014 GRD Development of Prototype Lead participant

“Red-NLAM” - reducing numbers in laboratory animal models (through improved artificial reproduction rates)

1 Feb 2014 to 31 Jan 2016

Awarded
£250,000
Total cost £720,008

In the UK alone, 1.8 million mice were used in breeding programmes for production of transgenic mice in 2012, according to Home office figures (about 48% of all animal used in research). The creation of genetically modified animals, primarily mice and rats, has revolutionised our understanding of disease processes in animal models. Transgenic biotechnolog...

Product types

Collaborative R&D Feasibility Studies GRD Development of Prototype Study